{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:12Z","timestamp":1787020932790,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030091","name":"Maine Office of Behavioral Health","doi-asserted-by":"publisher","award":["Maine Office of Behavioral Health"],"award-info":[{"award-number":["Maine Office of Behavioral Health"]}],"id":[{"id":"10.13039\/100030091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Justice"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of our study was to evaluate the post-release outcomes of incarcerated individuals with opioid use disorder (OUD) treated with extended-release buprenorphine (XRB) in a rural county jail. Administrative data were collected from a pilot program within a jail in Maine that introduced XRB treatment in 2022 and a comparable jail utilizing sublingual buprenorphine (SLB) during the same period to compare post-release outcomes. Log-binomial regression models were used to estimate the risk ratio (RR) and 95% confidence interval (CI) for jail use of XRB vs. SLB on post-release community buprenorphine continuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From September 2022 to September 2023, 70 individuals who received XRB were released from the pilot jail and 130 individuals who received SLB were released from the comparison jail. After adjusting for age, sex, and buprenorphine use at entry to jail, individuals released from the pilot jail were almost 3 times (adjusted RR\u2009=\u20092.67, 95% CI 1.84, 3.88) as likely to continue community buprenorphine treatment post-release relative to the comparison jail. In addition, utilization of XRB allowed for expanded access to OUD treatment, was well tolerated, and reduced medication diversion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this pilot program in Maine, XRB treatment during incarceration was associated with higher post-release community buprenorphine continuation when compared to individuals treated with SLB. These findings provide strong evidence for the superiority of XRB vs. SLB for the treatment of OUD in jail settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40352-024-00281-w","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T03:02:24Z","timestamp":1719543744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Community buprenorphine continuation post-release following extended release vs. sublingual buprenorphine during incarceration: a pilot project in Maine"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4098-6811","authenticated-orcid":false,"given":"Alane B.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gelsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadie M.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"issue":"4","key":"281_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/ADM.0000000000000942","volume":"16","author":"J Berk","year":"2022","unstructured":"Berk, J., Del Pozo, B., Rich, J. D., & Lee, J. D. (2022). Injecting opioid use disorder treatment in jails and prisons: The potential of extended-release Buprenorphine in the Carceral setting. Journal of Addiction Medicine, 16(4), 396\u2013398. https:\/\/doi.org\/10.1097\/ADM.0000000000000942","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"281_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","volume":"356","author":"IA Binswanger","year":"2007","unstructured":"Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007). Release from prison\u2013a high risk of death for former inmates. New England Journal of Medicine, 356(2), 157\u2013165. https:\/\/doi.org\/10.1056\/NEJMsa064115","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"281_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","volume":"159","author":"IA Binswanger","year":"2013","unstructured":"Binswanger, I. A., Blatchford, P. J., Mueller, S. R., & Stern, M. F. (2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159(9), 592\u2013600. https:\/\/doi.org\/10.7326\/0003-4819-159-9-201311050-00005","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"281_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40352-023-00209-w","volume":"11","author":"L Cates","year":"2023","unstructured":"Cates, L., & Brown, A. R. (2023). Medications for opioid use disorder during incarceration and post-release outcomes. Health Justice, 11(1), 4. https:\/\/doi.org\/10.1186\/s40352-023-00209-w","journal-title":"Health Justice"},{"issue":"1","key":"281_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13722-022-00288-4","volume":"17","author":"A Cheng","year":"2022","unstructured":"Cheng, A., Badolato, R., Segoshi, A., McDonald, R., Malone, M., Vasudevan, K., Badiei, B., Sugarman, A., Macdonald, R., Mangat, J., Giftos, J., Lee, J. D., & Tofighi, B. (2022). Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: An in-depth qualitative study. Addict Sci Clin Pract, 17(1), 4. https:\/\/doi.org\/10.1186\/s13722-022-00288-4","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"281_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/ADM.0000000000000635","volume":"14","author":"K Crotty","year":"2020","unstructured":"Crotty, K., Freedman, K. I., & Kampman, K. M. (2020). Executive summary of the focused update of the ASAM National Practice Guideline for the treatment of opioid Use Disorder. Journal of Addiction Medicine, 14(2), 99\u2013112. https:\/\/doi.org\/10.1097\/ADM.0000000000000635","journal-title":"Journal of Addiction Medicine"},{"key":"281_CR7","doi-asserted-by":"publisher","first-page":"109254","DOI":"10.1016\/j.drugalcdep.2021.109254","volume":"231","author":"EA Evans","year":"2022","unstructured":"Evans, E. A., Wilson, D., & Friedmann, P. D. (2022). Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug and Alcohol Dependence, 231, 109254. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109254","journal-title":"Drug and Alcohol Dependence"},{"key":"281_CR8","unstructured":"Feinberg, R., Esenstad, A., Cannon, R., Staatz, C., Peris, K., Bokota, L., Luca, D. L., & Stein, J. (2023). Health Care Transitions for Individuals Returning to the Community from a Public Institution: Promising Practices Identified by the Medicaid Reentry Stakeholder Group. January, 26 2023. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. Retrieved November 26 from https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/d48e8a9fdd499029542f0a30aa78bfd1\/health-care-reentry-transitions.pdf"},{"issue":"4","key":"281_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","volume":"75","author":"TC Green","year":"2018","unstructured":"Green, T. C., Clarke, J., Brinkley-Rubinstein, L., Marshall, B. D. L., Alexander-Scott, N., Boss, R., & Rich, J. D. (2018). Postincarceration Fatal overdoses after implementing medications for Addiction Treatment in a Statewide Correctional System. JAMA Psychiatry, 75(4), 405\u2013407. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4614","journal-title":"JAMA Psychiatry"},{"key":"281_CR10","doi-asserted-by":"publisher","first-page":"100133","DOI":"10.1016\/j.dadr.2023.100133","volume":"6","author":"C Heidbreder","year":"2023","unstructured":"Heidbreder, C., Fudala, P. J., & Greenwald, M. K. (2023). History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug Alcohol Depend Rep, 6, 100133. https:\/\/doi.org\/10.1016\/j.dadr.2023.100133","journal-title":"Drug Alcohol Depend Rep"},{"key":"281_CR11","unstructured":"Homans, M., Allen, D. M., & Mazariegos, Y. (2023). A Review of Medication Assisted Treatment (MAT) in United States Jails and Prisons. June 2023. Retrieved September 2 from https:\/\/cchcs.ca.gov\/wp-content\/uploads\/sites\/60\/MAT-in-United-States-Jails-and-Prisons-Final.pdf"},{"issue":"11","key":"281_CR12","doi-asserted-by":"publisher","first-page":"e2342222","DOI":"10.1001\/jamanetworkopen.2023.42222","volume":"6","author":"DB Hoover","year":"2023","unstructured":"Hoover, D. B., Korthuis, P. T., Waddell, E. N., Foot, C., Conway, C., Crane, H. M., Friedmann, P. D., Go, V. F., Nance, R. M., Pho, M. T., Satcher, M. F., Sibley, A., Westergaard, R. P., Young, A. M., & Cook, R. (2023). Recent incarceration, Substance Use, Overdose, and Service Use among people who Use drugs in Rural communities. JAMA Netw Open, 6(11), e2342222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.42222","journal-title":"JAMA Netw Open"},{"key":"281_CR13","unstructured":"Indivior, U. K. L. (2022). SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use. Updated September 2023 Retrieved December 21 from https:\/\/www.sublocade.com\/Content\/pdf\/prescribing-information.pdf"},{"key":"281_CR14","unstructured":"Indivior, U. K. L. (2023). SUBOXONE\u00ae(buprenorphine and naloxone) sublingual film, for sublingual or buccal use. Retrieved December 21 from https:\/\/www.suboxone.com\/pdfs\/prescribing-information.pdf"},{"key":"281_CR15","unstructured":"Kaiser Family Foundation (2023a). Medicaid Waiver Tracker: Approved and Pending Sect.\u00a01115 Waivers by State. Table 1: Sect.\u00a01115 Eligibility Changes - Expanded Eligibility Groups - Justice-Involved. October 26, 2023. Retrieved November 26 from https:\/\/www.kff.org\/medicaid\/issue-brief\/medicaid-waiver-tracker-approved-and-pending-section-1115-waivers-by-state\/#Table1"},{"key":"281_CR16","unstructured":"Kaiser Family Foundation (2023b). State Health Facts: Opioid Overdose Death Rates and All Drug Overdose Death Rates per 100,000 Population (Age-Adjusted). Retrieved October 4 from https:\/\/www.kff.org\/state-category\/mental-health\/opioids\/"},{"issue":"9","key":"281_CR17","doi-asserted-by":"publisher","first-page":"e2123032","DOI":"10.1001\/jamanetworkopen.2021.23032","volume":"4","author":"JD Lee","year":"2021","unstructured":"Lee, J. D., Malone, M., McDonald, R., Cheng, A., Vasudevan, K., Tofighi, B., Garment, A., Porter, B., Goldfeld, K. S., Matteo, M., Mangat, J., Katyal, M., Giftos, J., & MacDonald, R. (2021). Comparison of Treatment Retention of adults with opioid addiction managed with extended-release buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release from Jail. JAMA Netw Open, 4(9), e2123032. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.23032","journal-title":"JAMA Netw Open"},{"issue":"3","key":"281_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/add.16071","volume":"118","author":"S Lim","year":"2023","unstructured":"Lim, S., Cherian, T., Katyal, M., Goldfeld, K. S., McDonald, R., Wiewel, E., Khan, M., Krawczyk, N., Braunstein, S., Murphy, S. M., Jalali, A., Jeng, P. J., MacDonald, R., & Lee, J. D. (2023). Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17. Addiction, 118(3), 459\u2013467. https:\/\/doi.org\/10.1111\/add.16071","journal-title":"Addiction"},{"issue":"5","key":"281_CR19","doi-asserted-by":"publisher","first-page":"e219041","DOI":"10.1001\/jamanetworkopen.2021.9041","volume":"4","author":"N Lintzeris","year":"2021","unstructured":"Lintzeris, N., Dunlop, A. J., Haber, P. S., Lubman, D. I., Graham, R., Hutchinson, S., Arunogiri, S., Hayes, V., Hjelmstrom, P., Svedberg, A., Peterson, S., & Tiberg, F. (2021). Patient-reported outcomes of treatment of opioid dependence with Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA Netw Open, 4(5), e219041. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.9041","journal-title":"JAMA Netw Open"},{"key":"281_CR20","unstructured":"Maine Department of Health and Human Serivces, O. o. M. S (2023). Extended-Release Buprenorphine Clinical Use Criteria. June 23, 2023. Retrieved December 21 from https:\/\/www.maine.gov\/dhhs\/oms\/providers\/provider-bulletins\/extended-release-buprenorphine-clinical-use-criteria-2023-06-23"},{"issue":"5","key":"281_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/0891241617737814","volume":"47","author":"L Martin","year":"2018","unstructured":"Martin, L. (2018). Free but still walking the Yard: Prisonization and the problems of Reentry. Journal of Contemporary Ethnography, 47(5), 671\u2013694. https:\/\/doi.org\/10.1177\/0891241617737814","journal-title":"Journal of Contemporary Ethnography"},{"key":"281_CR22","doi-asserted-by":"publisher","first-page":"108851","DOI":"10.1016\/j.jsat.2022.108851","volume":"142","author":"RA Martin","year":"2022","unstructured":"Martin, R. A., Berk, J., Rich, J. D., Kang, A., Fritsche, J., & Clarke, J. G. (2022). Use of long-acting injectable buprenorphine in the correctional setting. Journal of Substance Abuse Treatment, 142, 108851. https:\/\/doi.org\/10.1016\/j.jsat.2022.108851","journal-title":"Journal of Substance Abuse Treatment"},{"key":"281_CR23","unstructured":"Maruschak, L. M., Bronson, J., & Alper, M. (2021). Survey of Prison Inmates, 2016 Alcohol and Drug Use and Treatment Reported by Prisoners. July 2021, NCJ 252641. U.S. Department of Justic, Bureau of Justice Statistics. Retrieved November 11 from https:\/\/bjs.ojp.gov\/sites\/g\/files\/xyckuh236\/files\/media\/document\/adutrpspi16st.pdf"},{"issue":"9","key":"281_CR24","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/j.1360-0443.2010.02990.x","volume":"105","author":"EL Merrall","year":"2010","unstructured":"Merrall, E. L., Kariminia, A., Binswanger, I. A., Hobbs, M. S., Farrell, M., Marsden, J., Hutchinson, S. J., & Bird, S. M. (2010). Meta-analysis of drug-related deaths soon after release from prison. Addiction, 105(9), 1545\u20131554. https:\/\/doi.org\/10.1111\/j.1360-0443.2010.02990.x","journal-title":"Addiction"},{"key":"281_CR25","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and, & Medicine, N. A. S. E. M. (2019). Medications for opioid use disorder save lives. National Academies. https:\/\/doi.org\/10.17226\/25310","DOI":"10.17226\/25310"},{"key":"281_CR26","unstructured":"O\u2019Connor, A., Letourneau, L., & Smith, G. (2022). Maine Opioid Response Clinical Advisory Committee: Proposed Position on Enhancing Access to Extended-Release Buprenorphine for Patients with Opioid Use Disorder. Retrieved December 21 from https:\/\/www.maine.gov\/future\/sites\/maine.gov.future\/files\/inline-files\/XRB_Opioid%20Clin%20Adv%20Comm%20Statement.pdf"},{"issue":"9","key":"281_CR27","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2105\/AJPH.2018.304514","volume":"108","author":"SI Ranapurwala","year":"2018","unstructured":"Ranapurwala, S. I., Shanahan, M. E., Alexandridis, A. A., Proescholdbell, S. K., Naumann, R. B., Edwards, D. Jr., & Marshall, S. W. (2018). Opioid overdose mortality among former North Carolina inmates: 2000\u20132015. American Journal of Public Health, 108(9), 1207\u20131213. https:\/\/doi.org\/10.2105\/AJPH.2018.304514","journal-title":"American Journal of Public Health"},{"key":"281_CR28","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. Bmj, 357, j1550. https:\/\/doi.org\/10.1136\/bmj.j1550","journal-title":"Bmj"},{"key":"281_CR29","unstructured":"The National Center on Addiction and Substance Abuse (NCASA) (2010). Behind Bars II: Substance Abuse and America\u2019s Prison Population. Columbia University. Retrieved October 4 from https:\/\/www.ojp.gov\/ncjrs\/virtual-library\/abstracts\/behind-bars-ii-substance-abuse-and-americas-prison-population"},{"key":"281_CR30","unstructured":"Weizman, S., Perez, J., Manoff, I., Baney, M., & El-Sabawi, T. (2021). National Snapshot: Access To Medications For Opioid Use Disorder In U.S. Jails And Prisons. O\u2019Neill Institute for National and Global Health Law at Georgetown Law Center (July Retrieved March 29 from https:\/\/oneill.law.georgetown.edu\/wp-content\/uploads\/2021\/07\/National-Snapshot-Access-to-Medications-for-Opioid-Use-Disorder-in-U.S.-Jails-and-Prisons.pdf"},{"issue":"3","key":"281_CR31","doi-asserted-by":"publisher","first-page":"e180558","DOI":"10.1001\/jamanetworkopen.2018.0558","volume":"1","author":"TNA Winkelman","year":"2018","unstructured":"Winkelman, T. N. A., Chang, V. W., & Binswanger, I. A. (2018). Health, Polysubstance Use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open, 1(3), e180558. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.0558","journal-title":"JAMA Netw Open"},{"issue":"6","key":"281_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1089\/jchc.21.07.0063","volume":"28","author":"JSH Wong","year":"2022","unstructured":"Wong, J. S. H., Masson, S., Huang, A., Romm, D., Fong, M., Porter, T., Sharifi, N., Azar, P., & Mathew, N. (2022). Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine\/Naloxone Tablets in a correctional setting. Journal of Correctional Health Care : The Official Journal of the National Commission on Correctional Health Care, 28(6), 368\u2013371. https:\/\/doi.org\/10.1089\/jchc.21.07.0063","journal-title":"Journal of Correctional Health Care : The Official Journal of the National Commission on Correctional Health Care"},{"key":"281_CR33","unstructured":"Zeng, Z., & Minton, T. D. (2021). Census of Jails, 2005\u20132019 \u2013 Statistical Tables. October 2021, NCJ 255406. U.S. Department of Justice, Bureau of Justice Statistics. Retrieved November 25 from https:\/\/bjs.ojp.gov\/library\/publications\/census-jails-2005-2019-statistical-tables"}],"container-title":["Health &amp; Justice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40352-024-00281-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40352-024-00281-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40352-024-00281-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T03:06:00Z","timestamp":1719543960000},"score":1,"resource":{"primary":{"URL":"https:\/\/healthandjusticejournal.biomedcentral.com\/articles\/10.1186\/s40352-024-00281-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1186\/s40352-024-00281-w","relation":{},"ISSN":["2194-7899"],"issn-type":[{"value":"2194-7899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Granted and discussed in detail in the methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}